Post Traumatic Stress Disorder Clinical Trial
Official title:
Lofexidine Combined With Buprenorphine for Reducing Symptoms of Post-Traumatic Stress Disorder (PTSD) and Opioid Use Relapse in Veterans
The overall objective of the proposed study is to determine if lofexidine (LFX) as an adjunct to buprenorphine (BUP) treatment improves symptoms of both opioid use disorder (OUD) and Post-Traumatic Stress Disorder (PTSD). Other study objectives are to compare the safety, tolerability, and efficacy of BUP treatment alone, to BUP treatment with adjunct LFX, on measures of OUD and PTSD symptoms in Veterans with both prognosis .
The aim of this clinical trial is to evaluate the efficacy of Lucemyra™ (lofexidine; LFX), an alpha-2-adrenergic receptor (α2-AR) agonist, as a medication for the prevention of opiate relapse and the alleviation of post-traumatic stress disorder (PTSD) symptoms in opiate-dependent veterans. Primary Endpoints : For OUD: Drug-Taking Behavior (% abstinent from illicit opioid use from Week 5 to Week 12 of the active treatment phase) is the primary efficacy endpoint for monitoring the effects of treatment on OUD, which is measured by both urine drug screen (UDS; opioids are detectable for 1-4 days) and timeline follow-back (TLFB) interviews of drug/alcohol use. For PTSD: The primary efficacy endpoint for monitoring the effects of treatment on PTSD symptoms is mean change scores on the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (PCL-5), which is recommended by the Department of Veterans Affairs and the Department of Defense (VA/DoD) Clinical Practice Guideline as a quantitative measure of a patient's PTSD symptoms and response to treatment over time. Secondary Endpoints: For OUD: Drug-Taking Behavior (≥ 80% abstinent between Week 5 to Week 12), treatment duration (days in treatment), and scores on the Subjective Opiate Withdrawal Scale (SOWS), the Clinical Opiate Withdrawal Scale (COWS), and the Opioid Craving Visual Analog Scale (OC-VAS) are secondary efficacy endpoints for monitoring the effects of treatment on symptoms on OUD. For PTSD: The secondary efficacy endpoints for monitoring the effects of treatment on core symptoms of PTSD are CAPS-5 change score (between screening and Week 12). Population: 120 veteran participants will be recruited from within the MEDVAMC. The study population will consist of veterans diagnosed with OUD and potential or provisional PTSD who are seeking treatment. Phase: This is a Phase 2 randomized, double-blind, placebo-controlled, single-site, parallel groups, 12-week treatment study Duration: Enrollment period of 24 months. Participant duration is 18 weeks (consisting of 4 weeks screening, a 12-week treatment period, and a 2-week follow-up). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
| Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
| Recruiting |
NCT05934175 -
Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder
|
N/A | |
| Recruiting |
NCT05934162 -
Efficacy of Internet-delivered Cognitive-behavior Therapy for PTSD
|
N/A | |
| Completed |
NCT04460014 -
Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT
|
N/A | |
| Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
| Active, not recruiting |
NCT05992649 -
The Effect of Aquatic Physiotherapy on Veterans Suffering From PTSD - a 40-week Pilotproject
|
N/A | |
| Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
| Not yet recruiting |
NCT05331534 -
Effect of Attentional Therapy on Post-traumatic Stress Disorder
|
N/A | |
| Not yet recruiting |
NCT03649607 -
Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black
|
N/A | |
| Not yet recruiting |
NCT04076215 -
Biochemical and Physiological Response to Stressogenic Stimuli
|
N/A | |
| Not yet recruiting |
NCT02545192 -
A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments
|
Phase 1 | |
| Completed |
NCT02329418 -
Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit
|
N/A | |
| Active, not recruiting |
NCT00978484 -
A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder
|
Phase 3 | |
| Completed |
NCT00760734 -
Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)
|
Phase 1 | |
| Completed |
NCT03278171 -
Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
|
||
| Recruiting |
NCT05874362 -
People Bereaved by Violent Death : Negative Event Biases and Temporal Perception
|
N/A | |
| Terminated |
NCT03898843 -
Assisted Animal Therapy: ReAnimal
|
N/A | |
| Recruiting |
NCT04747379 -
Psychological Effect of Explicit Recall After Sedation (PEERS)
|
||
| Completed |
NCT03248167 -
Cannabidiol as a Treatment for AUD Comorbid With PTSD
|
Phase 1/Phase 2 |